OPEN END TURBO LONG - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 01:13:45 29/06/2024 am IST | ||
| 16 EUR | -1.90% |
|
| Current month | +9.89% | ||
| 1 month | +15.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 16 | -1.90% |
| 27/24/27 | 16.31 | +0.12% |
| 26/24/26 | 16.29 | +0.99% |
| 25/24/25 | 16.13 | -1.89% |
| 24/24/24 | 16.44 | +2.88% |
Delayed Quote Börse Stuttgart
Last update June 29, 2024 at 01:13 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MD5HKF |
| ISIN | DE000MD5HKF2 |
| Date issued | 23/06/2022 |
| Strike | 300.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.01 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.32 € |
|---|---|
| Lowest since issue | 1.99 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
